2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Blood Banking, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Vaccines, Non-Biological Therapies, Opioids, Women’s Health, Adverse Events, Biological Processes, Hematopoiesis, Metabolism, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Immunology, Immunodeficiency, Infectious Diseases, Bacterial, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

4709 Impact of the affordable care act on insurance coverage and healthcare utilization among patients with sickle cell disease: A difference-in-differences analysis

Joseph Brennan deBettencourt, MD, Monica Hulbert, MD2, Natasha M. Archer, MD, MPH3
3 Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, United States

Background: The effect of the Affordable Care Act (ACA) on insurance coverage and healthcare utilization in patients with sickle cell disease (SCD) has received limited exploration. Prior work has not shown significant Medicaid enrollment gains in this population despite expansion, raising questions about whether policy-level insurance coverage amendments translate into measurable access or utilization benefits for this high-need group.

Study Design and Methods: We performed a retrospective interrupted time series analysis with difference-in-differences (DiD) estimation using publicly available CDC Sickle Cell Data Collection Program data from California (Medicaid expansion, January 2014) and Georgia (non-expansion) for 2010–2018. We analyzed patients by age-group per state per year (7 age groups, 2 states, 9 years), analyzed separately for emergency department (ED) and inpatient encounters, as well as for the two combined. Models were weighted by SCD population size per age group. Parallel pre-trends and placebo testing (2012 pseudo-intervention) supported DiD validity; Medicare served as a negative control. Primary outcomes were proportions of Medicaid, private, and self-pay (as proxy for uninsured) encounters. Secondary outcomes included ED visits per person, admissions per person, proportion of admissions from the ED, 30-day readmission, length of stay, and hospital days per person. Benjamini-Hochberg correction was applied when making multiple comparisons.

Results: Both states experienced declines in self-pay ED and inpatient encounters over the study period. When looking at combined ED and inpatient encounters, California showed a significantly greater increase in Medicaid-covered encounters relative to Georgia (DiD +6.9%, p=0.0016, adjusted p= 0.0064) and a corresponding relative decrease in proportion of private insurance encounters (-2.2%, p=0.010, adjusted p=0.027) and self-pay encounters (-3.9%, p=0.0008, adjusted p=0.0064). Despite these coverage shifts, overall healthcare utilization did not significantly differ between states: ED visits per person and inpatient admissions per person remained similar pre- and post-ACA in both states. Unexpectedly, there was a significant relative decrease in the proportion of admissions originating from the ED in California compared to Georgia (DiD slope -0.026, p<0.001), while overall admission and ED visit rates were unchanged. Medicare-covered encounters, used as a negative control, showed no significant change in either state.

Conclusion: Medicaid expansion under the ACA was associated with significantly increased Medicaid coverage and decreased self-pay encounters among patients with SCD presenting for acute care in California relative to Georgia. While these coverage gains did not correspond to measurable reductions in overall healthcare utilization, a reduction in self-pay encounters could lead to a decrease in financial toxicity experienced by this population. The decreased proportion of ED-originating admissions in California, without a change in total admissions, may reflect increased use of alternative care settings such as infusion centers or planned admissions for preventative care, though this requires further study. These findings suggest that expanding insurance coverage alone may be insufficient to change overall acute care utilization patterns in SCD. Future study is needed to best understand public insurance coverage associated clinical and social outcomes, namely those related to healthcare utilization and financial toxicity.

Monica Hulbert, MD: No relevant conflicts of interest to declare.